• Health Care

DCGI approved Astra Zeneca’s Lynparza as a monotherapy for adjuvant treatment of patients with high-risk early breast cancer

·         Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer ·         New Data from OlympiA Phase…

• Latest

Eisai Receives Positive Opinion from EMA’s CHMP on Use of Antiepileptic Agent Fycompa in Pediatric Patients

Tokyo, September 23, 2020:  Eisai Co., Ltd. announced that it has received a positive opinion from the European Medicines Agency…

• New Launches

Lupin Launches Divalproex Sodium ER Tablets USP

Mumbai, September 23, 2020: Pharma major Lupin Limited (Lupin) announced the launch of Divalproex Sodium Extended-Release (ER) Tablets USP, 250 mg…

• Hospitals

Cadila Pharmaceuticals launches Obetocad, a generic Obeticholic Acid (Ocaliva®) in the liver therapy

Ahmedabad September 18, 2020: Cadila Pharmaceuticals launches Obetocad in India, a generic version of Ocaliva® (Obeticholic Acid) primarily used for…

Eisai’s Supplementary New Drug Application Submitted In Japan for Fycompa

As Monotherapy for Partial-Onset Seizures, Pediatric Indication for Partial-Onset Seizures, as Well as New Formulation Tokyo, February 03, 2019: Eisai Co., Ltd.…

Eisai’s Supplementary New Drug Application Submitted In Japan for Fycompa

As Monotherapy for Partial-Onset Seizures, Pediatric Indication for Partial-Onset Seizures, as Well as New Formulation Tokyo, January 31, 2019: Eisai…

• Extras

Lilly India enters the autoimmune segment with Olumiant™, a new once-daily oral therapy for Rheumatoid Arthritis

Mumbai, November 11, 2018: Eli Lilly and Company (India) Pvt. Ltd. (“Lilly India”) announced the launch of Olumiant™ (baricitinib). This…